此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

头颈癌分子和血液生物标志物、治疗和结果临床研究平台 (HEAT)

2026年11月5日 更新者:AIO-Studien-gGmbH

头颈癌分子和血液临床研究平台

Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.

研究概览

详细说明

The advent of checkpoint inhibitors has changed the treatment landscape in SCCHN and new treatment sequences have entered clinical practice.

More in-depth knowledge of tumor biomarkers are important measures for optimization of treatment strategies in SCCHN. In addition to this, investigations may involve other assessments, which will be explored separately, such as molecular testing. These tests are then linked to the core data set and will allow to associate such measures with outcomes. This concept is flexible and allows for rapid integration of contemporary research questions in a timely manner.

Furthermore, insights into the treatment reality for recurrent/metastatic salivary gland carcinoma and other rare tumor entities (SNUC, etc.) are urgently needed, as there is currently no established standard of care.

The monoclonal antibody cetuximab in combination with platinum and fluorouracil (EXTREME) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade.1 Recently, the immune checkpoint inhibitors (CPIs) nivolumab and pembrolizumab have changed the therapeutic landscape of patients with r/m SCCHN. Nivolumab is considered as therapeutic standard after failure of platinum-based therapy based on the results of the phase III Checkmate-141 trial.2 In addition, pembrolizumab has become the new standard in the first-line setting in combination with platinum/fluorouracil chemotherapy or as monotherapy for patients with programmed cell death ligand 1 (PD-L1) positive tumors based on the data from the phase III Keynote-048 trial.3 Moreover, cetuximab in combination with platinum and docetaxel (TPEx) has emerged as a less toxic alternative to the EXTREME regimen.4 Due to the shifting first-line treatment landscape, data to guide contemporary 2nd line therapy are scarce and the optimal treatment sequence remains vague.2,5,6 The implementation of biomarkers and selection of patients in a real-world setting are areas of academic interest. In addition, the assessment of treatment outcomes in rare entities are underrepresented in pivotal trials, and as a matter of fact, may be completely excluded. However, broad labels permit the use of novel agents, but a larger body of evidence is needed to substantiate such treatment choices. HEAT seeks to address these questions by inclusion of a real-world patient population and continuous assessment of oncological outcomes by means of a core clinical data set implemented into HEAT.

Overall, HEAT is a study platform, which continuously assesses clinical outcomes and modularly integrates additional measures to enable rapid answers to research questions.

研究类型

观察性的

注册 (估计的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Essen、德国、45147
        • 尚未招聘
        • Universitätsklinikum Essen
        • 接触:
      • Hanover、德国、30161
        • 招聘中
        • Onkologie/Studienzentrum am Raschplatz GbR
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult patients with histologically or cytologically confirmed malignancy of the head neck area including but not limited to

  • squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx
  • not amenable for curative treatment who receive palliative systemic treatment or best supportive care.

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to understand and willing to sign written informed consent
  • Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
  • Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
  • Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease

Exclusion Criteria: none

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Sociodemographic factors
大体时间:3 years

Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree

3 years
Treatments
大体时间:3 years

Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences

3 years
Response rates
大体时间:3 years

Response rates

3 years
Treatment decision
大体时间:3 years

Physician-reported parameters affecting treatment decision

3 years
Progression-free survival
大体时间:3 years

Progression-free survival

3 years
Time-to-treatment-failure
大体时间:3 years

Time-to-treatment-failure

3 years
Overall survival
大体时间:3 years

Overall survival

3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Victor Grünwald, Prof. Dr.、Universitätsklinikum Essen
  • 首席研究员:Michael Pogorzelski, Dr.、Universitätsklinikum Essen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月7日

初级完成 (估计的)

2030年2月1日

研究完成 (估计的)

2030年2月1日

研究注册日期

首次提交

2024年4月12日

首先提交符合 QC 标准的

2024年4月18日

首次发布 (实际的)

2024年4月24日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅